Ask the genius Paul Ashton to call this the inflection point in the history of PSDV.
Only way this goes up is when they fire the BOD and CEO and force them to take action to accelerate the agenda to introduce products to market faster. To think this guy thinks it was a genius idea to piggy back on Illuvien for Medidur approval does not look so much saner now does it? Illuvien was delayed 3 years and now we are 2 more years or more for Medidur approval. Forget about tethadur because this lame management is still nickle and dimeing the proposals or the value of the paper on which they will write the proposals.
Fire the bunch of idiots running this company and wasting investor money on watching the paint dry for eons.
Sentiment: Strong Sell
And they can dump it almost at will, no one will even know when they dump it onto unsuspecting investors. Seen that movie a 100 times.
Compare the efficacy of Zevalin compared to Rituxan and compare the annual revenue/sales for both drugs. For NHL patients including FL - Zevalin costs $28000 and is a single shot treatment compared to Rituxan which requires 12 shots in 2 years and costs nearly 10 fold.
Health care in USA sucks because doctors are paid upto 6-8% administration cost for drugs. Now apply 6% to 28000 vs 260000 and that is only for the drug admi. cost, 12 consultations vs 1 etc. are other money earners for the Onc/Hem. Do you think they really care for the patients convenience or the cost? Think again.
Wall St. thinks Illuvien is doomed when the smart money saw there was little chance of approval they bid this stock to $8 and shorted all the way up. Now upon approval they would not let the needle go higher than $5.
How many analysts cover Eyela compared to the 3 pathetic losers who showed up for Alimera CC. You would think more would be interested in knowing how Alimera/Illuvien would hurt Eyela sales and if they needed to take Eyela numbers down a bit. Looks like they do not care for this two bit #$%$.
PSDV management is playing dead and enjoying collecting their free money from shareholders, they just need to keep alive and keep the interest alive in PSDV enough to enjoy getting freebee shares, hefty salaries and bonuses. They do not care about the shareholders, at best they will release some PR every once in a wile or Paul will go put out a blog and boost interest in the stock.
it is a penny stock and the Co's management is running it as such. Blood sucking parasites the entire BOD of pSiVida including its Chairman and CEO.
Single shot vs 20 for Eyela is the problem. Doctors love 20 shots. More shots=more $$$ gor the Doctor to sffoard his BMW 5 series or better.
Worst case they are also impotent, they will never get anything done.
Shareholders are to blame because they believe everything the CEO and the board prints without questioning it and continue to reward the insiders with free shares, bonuses and salary increases.
First thing the shareholders need to do is to send a message to Paul it will not work in future and he will need to do better for the shareholders not himself. Start with not giving them any bonus shares and a hold on salary increases. If he wants to quit, better for the shareholders..
Bionics are like prosthetics and have nothing to do with drug delivery. I do agree that implanted drug delivery devices are important in several type of applications. Surgically implanted pumps are a big business, it requires a small surgery but something like silicon implants to deliver drugs are easier to manage, low risks and do not require surgery to remove the pump. Unlike surgical implants the risk of infections is dramatically reduced or eliminated. So, yes I agree there is a huge demand for silicon structures and I think FDA has a short sited and dumb approach to the approval process for such drug delivery implants. The need to full blown PIII trials should be eliminated in favor of reduced AE based studies only. As long as a full P3 study is done to demonstrate bio-availability and efficacy for implants in different parts of the body, it may be sufficient.
Due to blood-brain barrier if implants for delivering/regulating dopamine could be implanted in the brain via a minor surgery, it could be huge for several brain disorders like Parkinson.
Applications are endless, the stumbling block is the FDA and the Co. unwilling to talk to FDA in terms of changing its guidelines for evaluating silicon implants for drug delivery. If you keep going to traditional route it will take endless time.
I also think the Co. does NOT have a good strategy for Tethadur platform, they are too passive and slow in promoting themselves. Instead of seeking a partner, they should announce trials for low hanging fruits with higher rewards and go at it alone, partners will follow. I think all shareholders will be rewarded, but the management's insistence of conservative fiscal discipline is hurting the shareholders and could eventually help the insiders. Insiders are in no rush to cash the technology, they have time and shareholders are willing to give them more time by giving them free shares every year in addition to handsome salaries, bonuses and benefits. Very poor management.
yes, it means they cannot detail the product to specialists for new DME patients, but it does not limit the specialist to treat the patients anyway. It is eventually going to be dependent on the patient comfort and the specialist comfort. They could shoot one corticosteroid injection and follow it up with Illuvien on the next visit a month later. Need to see what the Insurer will allow for cash patients it is better than 20 shots in 3 years.
Sentiment: Strong Sell
#$%$, I sold all my shares yesterday. I do not believe they got approval.
Sentiment: Strong Sell
Looks like ALIM bulls are rolling over - relatively PSDV is holding well. Do not know for how long. last 1 hr....